The article offers information on primary amyloidosis (AL) which is caused by the deposition of monoclonal immunoglobulin light chains occurring in patients with some form of clonal plasma-cell dyscrasias. It highlights ...
Primary or AL amyloidosis results from a plasma cell dyscrasia in which fibrillar light chain protein deposition leads to organ failure and death. Standard treatment for AL amyloidosis has been oral melphalan and prednisone. However, this form of treatment modifies the natural history of this ...
The authors provide instruction on all forms of amyloidosis - including primary amyloidosis (AL), secondary amyloidosis (AA), and familial amyloidosis. With essential treatment algorithms, Amyloidosis: Diagnosis and Treatment is the gold-standard for all hematologists, oncologists, and internists caring...
AL amyloidosis (immunoglobulin light chain amyloidosis).This is the most common type and used to be called primary amyloidosis. AL stands for "amyloid light chains," which is the type of protein responsible for the condition. There’s no known cause, but it happens when your bone marrow makes...
Chemotherapy and/or bone marrow transplant may be highly effective for patients with primary amyloidosis that accompanies a form of bone marrow cancer called multiple myeloma. A bone marrow transplant is a procedure in which a patient's own bone marrow, which is often the source of amyloid ...
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to tre
In recent years, gene-editing technologies have revolutionised precision medicine, and human trials of this technology have been reported in cell-based cancer therapies and other genetic disorders. The same techniques have the potential to reverse mutations in monogenic primary immunodeficiencies (PIDs),...
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–3757. doi: 10.1200/JCO.2004.03.029. (Open in a new window)PubMed (Open in a new window)Web of Science ®(Open in a new window)...
Systemic immunoglobulin light chain amyloidosis Nat Rev Dis Primers, 4 (1) (2018), p. 38 View in ScopusGoogle Scholar 4. A Dispenzieri, MA Gertz, RA Kyle Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol, ...
30. A method for treating in an individual with systemic amyloidosis comprising administering an effective amount of a chimeric protein to the individual, wherein the chimeric protein comprises from N-terminal part to C-terminal part (i) a human serum amyloid P compound (SAP); (ii) a first ...